ALF 2020 Preliminary program

Thursday, 5th March 2020. 

15:00-19:00 ULTRASOUND IN CHRONIC LIVER DISEASES

Hands-on course for young hepatologists (University hospital centre Split)


Friday, 6th March 2020.

Cirrhosis and portal hypertension: from guidelines to individualized approach 

09:00-10:30  SESSION I: RECOGNIZING THE PROBLEM

Chairs: Ljubicic N, Ostojic R, Puljiz Z

Noninvasive tests for fibrosis and cirrhosis: are we ready for screening? (Gines P , ES)

What about steatosis and NAFLD? (Mikolasevic I, HR)

Noninvasive tests for portal hypertension (Grgurevic I, HR)

How close we are to HCV elimination: data from Central Europe (Flisiak R, PL)

11:00-12:30 SESSION II: PREVENTING THE COMPLICATIONS 

Chairs: Tonkic A, Trgo G

Primary prevention of variceal bleeding (Bosch J, ES)

The role of gut microbioma in progression of cirrhosis and portal hypertension (Papp M, HU)

Treatment of hepatitis C in patients with cirrhosis (Filipec-Kanizaj T, HR)

Treatment of PBC (Jarcuska P, SK)

Nutritional issues in cirrhosis (Krznaric Z, HR)

12:30-13:30 LUNCH

13:30-15:00 SESSION III: PATIENT WITH ADVANCED CIRRHOSIS AND PORTAL HYPERTENSION I

Chairs: Milic S, Bosch J

Endoscopic treatment of acute variceal bleeding (Puljiz Z, HR)

The role of TIPS (Patch D/Potts J, UK)

Secondary prevention of variceal bleeding: guided or blinded? (Graupera I, ES)

Renal injury in cirrhosis (Knezevic-Stromar I, HR)

Severe alcoholic hepatitis (Virovic Jukic L, HR)

15:30-17:00 SECTION IV: PATIENT WITH ADVANCED CIRRHOSIS AND PORTAL HYPERTENSION II

Chairs: Hrstic I, Ladic D

Frailty in cirrhosis (Skladany L, SK)

Splanhnic thrombosis in cirrhosis: approach to treatment and monitoring (La Mura V, IT)

Long-term outcome of patients with alcoholic liver cirrhosis (Stauber R, AT)

Impact of outpatient care on survival in alcoholic cirrhosis (Tepes B, SI)

20:00 Dinner for the participants


Saturday, 7th March 2020. 

09:00-10:30 SECTION V: PERSONALIZED AND PRECISION MEDICINE IN CIRRHOSIS AND PH

Chairs: Bonacin D, LaMura V

Natural history and genetic determinants for progression of cirrhosis and portal hypertension (Tsochatzis E, UK) Tsochatzis E UK

Artificial neural network prognostic modeling in cirrhosis (Salkic N, BH)

Screening for HCC: current reccomendations (Milovanovic T, RS)

New targets for the treatment of portal hypertension (Schwabl P, AT)

10:30 CONCLUDING REMARKS